Multicellular tumor spheroid models to explore cell cycle checkpoints in 3D

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Laurent, Jennifer ^a,b   Frongia, Céline ^a,b   Cazales, Martine ^a,b   Mondesert, Odile ^a,b   Ducommun, Bernard ^a,b,c   Lobjois, Valérie ^a,b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UPS   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

3D; Cell cycle; Checkpoint; Fucci reporters; Spheroid

Indexed keywords

EDOXUDINE; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; MEVINOLIN;

ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL CYCLE REGULATION; CELL ENGINEERING; CELL PROLIFERATION; CELL SURFACE; CELLULAR DISTRIBUTION; DNA DAMAGE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; IMMUNOFLUORESCENCE TEST; MULTICELLULAR SPHEROID; PANCREAS ADENOCARCINOMA; TUMOR GROWTH; TUMOR MODEL; TUMOR SPHEROID;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL CYCLE CHECKPOINTS; CYTOTOXINS; DEOXYCYTIDINE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84873470449     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-73     Document Type: Article

References (25)

1. Dubessy C, Merlin JM, Marchal C, Guillemin F. Spheroids in radiobiology and photodynamic therapy. Crit Rev Oncol Hematol 2000, 36(2-3):179-192. 10.1016/S1040-8428(00)00085-8, 11033305.
2. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988, 240(4849):177-184. 10.1126/science.2451290, 2451290.
3. Friedrich J, Ebner R, Kunz-Schughart LA. Experimental anti-tumor therapy in 3-D: spheroids-old hat or new challenge?. Int J Radiat Biol 2007, 83(11-12):849-871. 10.1080/09553000701727531, 18058370.
4. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010, 148(1):3-15. 10.1016/j.jbiotec.2010.01.012, 20097238.
5. Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance?. Crit Rev Oncol Hematol 2000, 36(2-3):193-207. 10.1016/S1040-8428(00)00086-X, 11033306.
6. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004, 9(4):273-285. 10.1177/1087057104265040, 15191644.
7. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010, 16(2):376-383. 10.1158/1078-0432.CCR-09-1029, 2939735, 20068082.
8. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009, 9(3):153-166.
9. Degenhardt Y, Lampkin T. Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 2010, 16(2):384-389. 10.1158/1078-0432.CCR-09-1380, 20068088.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.
11. Carpinelli P, Moll J. Aurora kinases and their inhibitors: more than one target and one drug. Adv Exp Med Biol 2008, 610:54-73. 10.1007/978-0-387-73898-7_5, 18593015.
12. Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011, 137(10):1409-1418. 10.1007/s00432-011-1039-4, 21877198.
13. Lazo JS, Wipf P. Is Cdc25 a druggable target?. Anticancer Agents Med Chem 2008, 8(8):837-842. 10.2174/187152008786847738, 2752834, 19075566.
14. Vassilev LT. Cell cycle synchronization at the G2/M phase border by reversible inhibition of CDK1. Cell Cycle 2006, 5(22):2555-2556. 10.4161/cc.5.22.3463, 17172841.
15. Carrassa L, Damia G. Unleashing Chk1 in cancer therapy. Cell Cycle 2011, 10(13):2121-2128. 10.4161/cc.10.13.16398, 21610326.
16. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011, 17(2):88-96. 10.1016/j.molmed.2010.10.009, 21087899.
17. Dufau I, Frongia C, Sicard F, Dedieu L, Cordelier P, Ausseil F, Ducommun B, Valette A. Multicellular Tumor Spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics. Application to the gemcitabine / CHK1 inhibitor combination in pancreatic cancer. BMC Cancer 2012, 12(1):15. 10.1186/1471-2407-12-15, 3280152, 22244109.
18. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010, 11(2):174-183. 10.1016/S1470-2045(09)70262-1, 20152769.
19. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, Kashiwagi S, Fukami K, Miyata T, Miyoshi H. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008, 132(3):487-498. 10.1016/j.cell.2007.12.033, 18267078.
20. Javanmoghadam-Kamrani S, Keyomarsi K. Synchronization of the cell cycle using lovastatin. Cell Cycle 2008, 7(15):2434-2440.
21. Zhong WB, Hsu SP, Ho PY, Liang YC, Chang TC, Lee WS. Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway. Biochem Pharmacol 2011, 82(11):1663-1672. 10.1016/j.bcp.2011.08.021, 21907187.
22. LaRue KE, Khalil M, Freyer JP. Microenvironmental regulation of proliferation in multicellular spheroids is mediated through differential expression of cyclin-dependent kinase inhibitors. Cancer Res 2004, 64(5):1621-1631. 10.1158/0008-5472.CAN-2902-2, 14996720.
23. Xouri G, Lygerou Z, Nishitani H, Pachnis V, Nurse P, Taraviras S. Cdt1 and geminin are down-regulated upon cell cycle exit and are over-expressed in cancer-derived cell lines. Eur J Biochem 2004, 271(16):3368-3378. 10.1111/j.1432-1033.2004.04271.x, 15291814.
24. Frongia C, Lorenzo C, Gianni F, Prevost GP, Ducommun B, Lobjois V. 3D imaging of the response to CDC25 inhibition in multicellular spheroids. Cancer Biol Ther 2009, 8(23):2230-2236.
25. Walker F, Zhang HH, Burgess AW. Identification of a novel EGF-sensitive cell cycle checkpoint. Exp Cell Res 2007, 313(3):511-526. 10.1016/j.yexcr.2006.10.026, 17157295.